Business Wire·Aug 24, 2026, 7:00 AM ET

AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer

ANTX

AN2 Therapeutics, Inc. appointed Cameron Trenor, M.D. as its new Chief Medical Officer.
Dr. Trenor brings over two decades of clinical, translational, & drug development leadership experience across rare diseases, hematology, oncology, immunology, & metabolic disorders.
Most recently, Dr. Trenor served as Chief Medical Officer at Cellarity, where he established its medical organization, led its first IND submission, & initiated a global first-in-human clinical study.
Prior to Cellarity, Dr. Trenor was Executive Medical Director at Forma Therapeutics, where he led global clinical development for etavopivat & supported its advancement into Phase 3 trials.
Earlier in his career, Dr. Trenor led clinical & translational programs in hematology & rare diseases at Novartis Institutes for BioMedical Research.
Dr. Trenor remains a practicing pediatric hematologist-oncologist at Boston Children's Hospital & has authored approximately 60 peer-reviewed research publications.
Dr. Trenor holds a B.S. in Biology from Tufts University, an M.D. from the University of Tennessee College of Medicine, & a Master of Medical Sciences in Clinical Investigation from Harvard Medical School.
He completed residency & fellowship training through Boston Children's Hospital, Boston Medical Center, & Dana-Farber Cancer Institute, & is board-certified in Pediatric Hematology-Oncology.
Eric Easom, Co-Founder, President, & CEO of AN2 Therapeutics, welcomed Dr. Trenor & thanked outgoing Senior Scientific Advisor Dr. George H. Talbot for his leadership & contributions.
AN2 Therapeutics expects three Phase 2 studies to be active in 2026, has two preclinical oncology candidates, & continues advanced research on targets in oncology, bone disorders, & infectious diseases.
The company utilizes a boron chemistry platform to develop novel small molecule therapeutics for hematologic diseases, infectious diseases, & oncology.